• By Donald Zuhn –-

    USPTO and EAPO Establish PPH Pilot Program

    Eurasian Patent OfficeIn a notice issued in the Official Gazette (1446 OG 52) last month, the U.S. Patent and Trademark Office announced that it was implementing a Patent Prosecution Highway (PPH) pilot program with the Eurasian Patent Office of the Eurasian Patent Organization (EAPO).  PPH programs permit applicants who receive a positive ruling on patent claims from one participating office to request accelerated prosecution of corresponding claims in another participating office.

    Because the EAPO is not currently a Global or IP5 PPH participating office, the USPTO noted that it would be partnering with the EAPO on a bilateral basis only.  The three-year pilot program began on January 1, 2018 and may be extended if necessary to adequately assess the feasibility of the PPH program.

    Requirements for participation in the USPTO-EAPO PPH can be found here.


    USPTO Releases Revised MPEP

    MPEP CoverThe U.S. Patent and Trademark Office announced via a Patent Alert e-mail last month that the Ninth Edition, Revision 08.2017 of the Manual of Patent Examining Procedure (MPEP) has been released.  The new version of the MPEP includes changes to chapters 200, 700-1000, 1200, 1400, 1500, 1800, 2000-2300, 2500, and 2700.  According to the Office's Alert, Appendices L and R have been revised to include laws and rules as of August 31, 2017, and Appendices T and AI have been revised to reflect the PCT Articles, Rules, and Administrative Instructions that were in force as of July 1, 2017.  The new version of the MPEP can be accessed at the USPTO's MPEP webpage.


    USPTO to Offer Sessions on Structured Text Features

    EFS-WebLast fall, the U.S. Patent and Trademark Office announced that EFS-Web-registered and Private PAIR users could now file structured text via EFS-Web and access structured text submissions, structured text Office actions, and XML downloads via Private PAIR (see "USPTO News Briefs," October 25, 2017).  As a result, EFS-Web-registered users can submit application parts in DOCX format, and Private PAIR users have the option to download XML or DOCX versions of PDF documents.

    In a Patent Alert e-mail sent last month, the Office announced that members of the eCommerce Modernization (eMod) team will be conducting DOCX Info Sessions in which information regarding the new structured text features, including the ability to file structured text via EFS-Web and access structured text submissions, structured text office actions, and XML downloads via Private PAIR will be shared.  The sessions, which will be one hour in length and limited to 20 attendees, will include a demonstration.  According to the session registration page, four session dates and times are currently available:  March 7, 2018 at 2:00 pm ET; March 21, 2018 at 2:00 pm ET; April 5, 2018 at 2:00 pm ET; and April 18, 2018 at 11:30 am ET.

  • By Kevin E. Noonan –

    USPTO SealIn a decision from an appeal before the Patent Trial and Appeal Board following rejection of claims to an isolated nucleic acid apparently (to applicants) falling within the scope of U.S. Patent and Trademark Office Guidance setting forth Office policy for implementing the Supreme Court's decision in AMP v. Myriad Genetics is this assertion by the Board:

    Appellants cite as support the USPTO's 2014 . . . ("Interim Guidance").  In particular, Appellants points to Claim 2 of Example 7 in the Interim Guidance . . . —"Isolated nucleic acid comprising a sequence that has at least 90% identity to SEQ ID No. 1 and contains at least one substitution modification relative to SEQ ID No. 1"—which was found in the Interim Guidance to be patent eligible.  We are not persuaded.  As an initial matter, we are not bound by the Interim Guidance.  Furthermore, we find the instant claims distinguishable from the example in the Interim Guidance, which requires a specific type of mutation (substitution) and specifies that "[n]o substitution modifications of [the gene at issue] are known to occur in nature."

    Ex parte Lukyanov, U.S. Appl. Ser. No. 11/607,828 (appeal decided 05/25/2017) (emphasis added).

    In contrast, another panel of the Board found the following claim patent-eligible based on another Guidance:

    1.  A method for detecting and quantitating in a biological fluid sample from a human [a biomarker having a specific SEQ ID NO], comprising
        (a) contacting the sample with a labeled monoclonal or polyclonal antibody which specifically binds to said [biomarker] and
        (b) detecting and quantitating the resulting [biomarker]: antibody complex using an immunoassay, wherein said immunoassay
            (i) is not a radioimmunoassay, and
            (ii) has a limit of detection of about 50 pmol/L.

    Ex parte Bergmann, U.S. Appl. Ser. No. 10/551,298 (appeal decided 07/10/2017):

    It seems curious, and the source of inconsistent policy, for the PTAB to take the position that the Board can choose to ignore USPTO Guidances at its leisure (if not its whim) in view of the stance the Office has taken with regard to the importance of maintaining consistency in its policies in other situations.  For example, in convening an expanded panel for deciding whether filing a lawsuit asserting a patent waives sovereign immunity as a grounds to dismiss an inter partes review before the Board (it does; see "PTAB Decides Patent Infringement Lawsuit Waives Eleventh Amendment Sovereign Immunity to Inter Partes Review"), the expanded panel, which comprised Deputy Chief Administrative Patent Judge Scott R. Boalick, Vice Chief Patent Judges Jacqueline Wright Bonilla and Scott C. Weidenfeller, and Administrative Patent Judges Jennifer S. Bisk, Robert J. Weinschenk, and Charles J. Boudreau, in addition to the Chief Administrative Patent Judge, expressly set forth its reliance on the Chief Judge's authority under 35 U.S.C. § 6 to expand panels when issues before the Board are of exceptional importance or are "necessary to secure and maintain uniformity of the Board's decisions."  And a different Board panel excoriated counsel for the St. Regis Mohawk Tribe for filing a motion for discovery regarding whether there would be any attempt to "stack" the Board against it (see "The PTAB Strikes Back — Issues Order Prohibiting St. Regis Mohawk Tribe from Filing Any Additional Papers in IPR"), despite there being concern before the Federal Circuit (see "Yissum Research Development Co. v. Sony Corp.") and, less directly, the Supreme Court regarding this policy.  In the Tribe's motion that provoked the panel's vociferous response, the request cited portions of the Administrative Procedures Act (specifically, 5 U.S.C. § 554(d)) that others have alleged, and it seems reasonable to suspect, might be bruised if not violated by the enlarged panel practices employed by the PTAB, i.e., a prohibition on members of a PTAB panel from being "subject to the supervision or direction of an employee or agent engaged in the performance of investigative or prosecuting functions for an agency."  In addition, the request cited the prohibition on ex parte communications under 5 U.S.C. § 557 or, if such communications have occurred, that they be included in the public record.

    Article I courts, and the PTAB in particular, have a legitimate goal of providing consistent application of the law to applicants and, in the case of implementing the adversarial avenues the AIA created, developing a consistent body of procedural and substantive law.  To this end, for example, the PTAB has designated some (albeit few) cases precedential, thus providing notice to the public regarding how the Office can be expected to conduct the "trials" mandated by the statute.

    But the Board's efforts are a larger part of, and expressly dependent on, the authority of the Office through the Director (as Under Secretary of Commerce) "for providing policy direction and management supervision for the Office and for the issuance of patents and the registration of trademarks [] in a fair, impartial, and equitable manner."  35 U.S.C. § 3(2)(A).  Those duties include the powers to "establish regulations, not inconsistent with law" for "govern[ing] the conduct of proceedings in the Office."  35 U.S.C. § 2(2)(A).  However, those activities "shall be made in accordance with section 553 of title 5," 35 U.S.C. § 2(2)(A), which govern administrative rulemaking.  More fundamentally, the Office is established under statute so that while being "subject to the policy direction of the Secretary of Commerce" it "otherwise shall retain responsibility for decisions regarding the management and administration of its operations and shall exercise independent control of its budget allocations and expenditures, personnel decisions and processes, procurements, and other administrative and management functions in accordance with this title and applicable provisions of law."  35 U.S.C. § 1.  Finally, nothing in the enabling statute for establishing the PTAB arrogates to that body any powers or authority independent of or superior to the powers vested in the Director over operation of the Office.  35 U.S.C. § 6.

    Which brings us to the source of the Interim Guidance ignored by the PTAB in the Lukyanov case, the Office of Legal Administration, which operates within the Office of Patent Examination Policy.  According to the USPTO website, the OPLA has the following functions:

    The Office of Patent Legal Administration (OPLA) drafts regulations and develops practices for the examination of patent applications, as well as assists in the implementation of these new regulations and practices.  In addition, OPLA staff author rule packages published in the Federal Register, create Official Gazette notices, monitor public comments, and formulate Frequently Asked Questions (FAQs).  To reflect changes in law, rules, procedures, and policies, OPLA recommends updates to the Manual of Patent Examining Procedure (MPEP) as well as the forms used by the Patent Examining Corps (Corps) and external customers.  Lastly, OPLA prepares and delivers training to the Corps.

    Other OPLA staff duties include supporting post grant instruments such as reexamination proceedings and reissue applications, and treating applications for patent term extension and patent term adjustment.  OPLA has the authority to decide various petitions which have been delegated for consideration.  Legal advisors also deliver training on specialized subjects and patent law and procedure for the Office of Patent Training.

    Additionally, in its representative capacity of the USPTO, OPLA responds to inquiries about patent law and Office policies and procedures via letters, phone calls, lectures, presentations, and other contacts with members of the public and the patent bar.  OPLA also assists in the efforts to negotiate the harmonization of patent laws and other international matters.

    What is unclear is the statutory basis for the PTAB's evident conviction that it has the authority to ignore USPTO policies, as evinced by Guidances from the OPLA.  As an adjudicatory body it is reasonable for the Board to take the position that is needs the authority to decide how to apply such Guidances from the OPLA a particular case.  But in the language of the Lukyanov decision lingers a flavor of an assertion of a higher authority, along the lines of the Board having the responsibility to decide what the law is independent from and superior to the Office's administration.  This is consistent with the impression created by the chimerical nature of IPR and other adversarial review procedures established by the AIA, which are sometimes characterized as being in the nature of a trial and other times (when the characterization suits) are analogized to any other administrative procedure.  These various roles may have had the effect of engendering a belief that the Board has an obligation greater than its statutory brief, and this reasonably calls into question the legitimacy of its decisions.  Many have opined in the wake of new Director Iancu's confirmation on the matters requiring his attention.  The proper role of the PTAB in the policy-making hierarchy of the USPTO appears to be one of them.

  • By Michael Borella

    Federal Circuit SealAatrix brought an infringement action against Green Shades in the Middle District of Florida, alleging infringement of U.S. Patent Nos. 7,171,615 and 8,984,393.  Green Shades filed a 12(b)(6) motion to dismiss on the grounds that all asserted claims were not eligible for patent under 35 U.S.C. § 101.

    The patents in suit are directed to "designing, creating, and importing data into a viewable form on a computer so that a user can manipulate the form data and create viewable forms and reports."  In particular, a "form file is created using in-house form development tools and is designed to model the physical characteristics of an existing form, including the calculations and rule conditions required to fill in the form."  A data file "allows data from third-party applications to be seamlessly imported into the form file program to populate the form fields."  A "viewer generates a report by merging the data in the [data] file with the fields in the form file, performing calculations on the data, and allowing the user to review and change the field values."

    Claim 1 of the '615 patent recites:

    1.  A data processing system for designing, creating, and importing data into, a viewable form viewable by the user of the data processing system, comprising:
        (a) a form file that models the physical representation of an original paper form and establishes the calculations and rule conditions required to fill in the viewable form;
        (b) a form file creation program that imports a background image from an original form, allows a user to adjust and test-print the background image and compare the alignment of the original form to the background test-print, and creates the form file;
        (c) a data file containing data from a user application for populating the viewable form; and
        (d) a form viewer program operating on the form file and the data file, to perform calculations, allow the user of the data processing system to review and change the data, and create viewable forms and reports.

    The Supreme Court's Alice Corp. v. CLS Bank Int'l case set forth a two-part test to determine whether claims are directed to patent-eligible subject matter under § 101.  One must first decide whether the claim at hand is directed to a judicially-excluded law of nature, a natural phenomenon, or an abstract idea.  If so, then one must further decide whether any element or combination of elements in the claim is sufficient to ensure that the claim amounts to significantly more than the judicial exclusion.  But generic computer implementation of an otherwise abstract process does not qualify as "significantly more."  On the other hand, a claimed improvement to a computer or technological process is typically patent-eligible.

    Aatrix argued that Green Shades' motion should be denied so that the District Court could carry out claim construction.  The District Court ultimately granted the motion, and concluded that claim 1 of the '615 patent was "not directed to any tangible embodiment and therefore not directed to eligible subject matter."  This latter point was not argued by the parties.  The District Court also held that the Alice test rendered the remaining claims abstract, without an inventive concept, and therefore invalid as well.

    Aatrix moved for the District Court to reconsider the judgment, as well as for leave to amend its complaint.  Particularly, Aatrix wished to file a second amended complaint that provided evidence that would preclude a § 101 dismissal on the pleadings.  The District Court denied this request, merely stating that "[u]pon consideration of the filings and the relevant case law, the [district court] sees no reason to reconsider its prior determination."  Aatrix appealed.

    The majority opinion began by noting that the Federal Circuit has held that patent eligibility under § 101 can be determined on the pleadings, but that "[t]his is true only when there are no factual allegations that, taken as true, prevent resolving the eligibility question as a matter of law."  On the other hand, "[i]f there are claim construction disputes . . . either the court must proceed by adopting the non-moving party's constructions . . . or the court must resolve the disputes to whatever extent is needed to conduct the § 101 analysis, which may well be less than a full, formal claim construction."

    Here, the Federal Circuit found that the District Court erred in its determination that claim 1 is not directed to a tangible embodiment.  While the case law has long held that claims directed to nothing more than signals or data structures do not fall into any of the four categories of patentable subject matter, Aatrix's system claim "requires a computer operating software, a means for viewing and changing data, and a means for viewing forms and reports."  Thus, the system is tangible.

    The District Court also erred in denying Aatrix the opportunity to amend its complaint.  The District Court did so without explanation.  But the Federal Circuit viewed the second amended complaint as including factual allegations that "if accepted as true, establish that the claimed combination contains inventive components and improves the workings of the computer."  Notably, the second amended complaint included specific allegations regarding the technical improvements of, and problems solved by, the claimed inventions.  If accepted as true, they would "contradict the district court's conclusion that the claimed combination was conventional or routine."  As a consequence, the District Court's dismissal was an abuse of discretion, and premature.

    For these reasons, the dismissal of the case was vacated, and the matter was remanded to the District Court for further proceedings.

    Judge Reyna concurred in part and dissented in part.  He agreed that the District Court erred in its characterization of claim 1 being directed to an intangible embodiment, and believed that this conclusion led the District Court to improperly deny Aatrix's motion to file a second amended complaint.  He took issue, however, with "with the majority's broad statements on the role of factual evidence in a § 101 inquiry," noting that this determination is a matter of law.

    Specifically, he wrote:

    [T]he majority opinion attempts to shift the character of the § 101 inquiry from a legal question to a predominately factual inquiry.  The risk of this approach is that it opens the door in both steps of the Alice inquiry for the introduction of an inexhaustible array of extrinsic evidence, such as prior art, publications, other patents, and expert opinion.  Similarly, the majority opinion strongly suggests that the district court must require claim construction where the meaning of a claim term is placed in controversy, even where, as here, proposed claim constructions are not presented to the court.  One effect of this approach is that a plaintiff facing a 12(b)(6) motion may simply amend its complaint to allege extrinsic facts that, once alleged, must be taken as true, regardless of its consistency with the intrinsic record.

    Judge Reyna also pointed out that the new allegations and evidence from the second amended complaint were not before the Court, as "[t]here was no motion to dismiss filed challenging the Second Amended Complaint."  He noted that "[a]s an appellate court, we should not pass judgment on matters not addressed by the district court."

    Following so quickly on the heels of the Berkheimer v. HP case, the Federal Circuit once again used its remand power to address a § 101 dispute where there may be a matter of material fact as to whether a claimed invention is a technical improvement over conventional art.  While Berkheimer took place at the summary judgment stage, this case was decided on the pleadings.  If the opinions in these cases stand, it may become significantly more difficult for a challenger to invalidate claims under § 101.  The patentee need only explain how the specification describes that the claimed invention is a technical improvement over existing systems.  This will mean that far fewer § 101 cases are dismissed on the pleadings, and more will go to trial.

    On the other hand, the disagreement between the majority opinion and Judge Reyna point to a split in the Federal Circuit case law, with authority supporting both positions.  This tees up the issue of whether a § 101 analysis involves underlying issues of fact for en banc review.

    But lifting our heads up out of the details of the case law for a moment, how can the determination of whether an invention involves significantly more than well-known, conventional, and routine features be anything less than a factual inquiry in at least some situations?  What is well-known, conventional, and routine is defined by the prior art, and whether an invention is a technical improvement over this art should not be subject to sweeping and conclusory statements.

    Aatrix Software, Inc. v. Green Shades Software, Inc. (Fed. Cir. 2018)
    Panel: Circuit Judges Moore, Reyna, and Taranto
    Opinion by Circuit Judge Moore; opinion concurring-in-part and dissenting-in-part by Circuit Judge Reyna

  • CalendarFebruary 20, 2018 – "Patent-Eligibility in 2018: Current Status and Best Practices" (McDonnell Boehnen Hulbert & Berghoff LLP) – 10:00 am to 11:15 am (CT)

    February 20, 2018 – "Managing and Defending Against Patent Infringement Lawsuits: Best Strategies and Practical Tips Explored" (The Knowledge Group) – 3:00 to 4:00 pm (ET)

    February 21-22, 2018 – Advanced Summit on Life Sciences Patents (American Conference Institute) – New York, NY

    February 22, 2018 – "Managing Patent Infringement Risk in Product Development" (Strafford) – 1:00 to 2:30 pm (EST)

    February 22, 2018 – "PTAB on Wi-Fi One: What's Next for Appeals?" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET)

    February 22, 2018 – "Drafting Quality Patents: Avoiding 112 Rejections at the USPTO" (LexisNexis) – 12:00 pm (ET)

    February 26, 2018 – "Chinese Patent Developments" (Practising Law Institute) – 4:00 to 5:00 pm (Eastern)

    February 27, 2018 – "Patent Inventorship: Best Practices for Determination and Correction — Distinguishing Between Inventor and Contributor; Navigating Joint Inventorship, Disclosure of Ownership, Real Party in Interest" (Strafford) – 1:00 to 2:30 pm (EST)

    February 28, 2018 – "Going Global with Patents" (Bereskin & Parr) – 12:00 to 1:00 pm (EST)

    March 3, 2018 – "Patent Post-Grant Practice" (John Marshall Law School Center for Intellectual Property, Information & Privacy Law) – 9:00 am to 4:30 pm, Chicago, IL

    March 5-6, 2018 – Advanced Patent Law Seminar (Chisum Patent Academy) – Houston, TX

    March 8, 2018 – "Patent Exclusivity Health Checks for Small Molecules: Are Your U.S. Patents Ready to Maximize ROI? — Phase II Efficacy Trials, Phase III Clinical Trials, NDA Submission, Approval and Marketing" (Strafford) – 1:00 to 2:30 pm (EST)

    March 8-9, 2018 – Advanced Patent Law Seminar (Chisum Patent Academy) – Cincinnati, OH

    March 14, 2018 – Patent Litigation Seminar (New Jersey Intellectual Property Law Association) – 12:00 to 5:00 pm, Iselin, NJ

  • IPO #2The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "PTAB on Wi-Fi One: What's Next for Appeals?" on February 22, 2018 from 2:00 to 3:00 pm (ET).  Hon. Michael Tierney of the U.S. Patent & Trademark Office, Matthew Berkowitz of Shearman & Sterling LLP, Scott Kamholz of Covington & Burling LLP, and David Kelley of Ford Global Technologies LLC will discuss the Federal Circuit's decision in Wi-Fi One LLC v. Broadcom Corp. that PTAB time-bar determinations under 35 U.S.C. § 315(b) are appealable because they do not fall within the scope of the judicial-review prohibition of § 314(d).  The panel will also address the following topics:

    • The AIA's various time bars as adjudicated by the PTAB — and whether there is a standing inconsistency among PTAB panels.
    • On which other issues are litigants likely to press for appeals such as the naming of all interested parties, or the reach of estoppel.
    • Real-party-in-interest and privacy, because in practice many potential appeals involve situations with various parties including joint defense groups, indemnification, and patent aggregators.
    • How will the PTAB respond to increased demands for discovery?

    The registration fee for the webinar is $135 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Patent Inventorship: Best Practices for Determination and Correction — Distinguishing Between Inventor and Contributor; Navigating Joint Inventorship, Disclosure of Ownership, Real Party in Interest" on February 27, 2018 from 1:00 to 2:30 pm (EST).  Jill K. MacAlpine and Amanda K. Murphy of Finnegan Henderson Farabow Garrett & Dunner will provide guidance for patent counsel on identifying and determining inventorship, offer best practices for correcting errors regarding inventorship, and offer perspectives gained from working with the AIA since it was passed—and outline lessons from recent court decisions.  The webinar will review the following issues:

    • What key information does counsel need to determine inventorship?
    • What are the steps for counsel when inventorship must be corrected?
    • What is the AIA's impact on an inventorship determination?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • Bereskin & ParrBereskin & Parr will be offering a presentation entitled "Going Global with Patents" on February 28, 2018 from 12:00 to 1:00 pm (EST).  Isi Caulder of Bereskin & Parr, Stephen Yang of Co-Talent, and Andrea Hughes of Dehns will discuss how smart organizations obtain global patent coverage to maintain their competitive advantage.  The panel will also address the following topics:

    • Key factors for strategic selection of foreign patent protection
    • How to secure global patent protection on a cost and time effective basis
    • Tips for monetizing a global patent portfolio and identifying collaboration opportunities (cross-licensing)

    Those wishing to register for the presentation can do so here.

  • LexisNexisLexisNexis will be offering a webinar on "Drafting Quality Patents: Avoiding 112 Rejections at the USPTO" on February 22, 2018 at 12:00 pm (ET).  Gene Quinn of IPWatchdog.com and Dave Stitzel of Reed Tech® will discuss best practices for filing a robust application to avoid 112 rejections and associated problems, and will address the following topics:

    • Indefiniteness: Nautilus (SCOTUS standard) versus In re Packard (USPTO standard)
    • Identifying and Interpreting 112(f) means plus function limitations
    • Alternative and Negative Limitations
    • Relational and Exemplary Language
    • Numerical Ranges and Amount Limitation

    Those interested in registering for the webinar, can do so here.

  • Strafford #1Strafford will be offering a webinar entitled "Patent Exclusivity Health Checks for Small Molecules: Are Your U.S. Patents Ready to Maximize ROI? — Phase II Efficacy Trials, Phase III Clinical Trials, NDA Submission, Approval and Marketing" on March 8, 2018 from 1:00 to 2:30 pm (EST).  Thomas L. Irving, Shana K. Cyr, Mark J. Feldstein, and John D. Livingstone of Finnegan Henderson Farabow Garrett & Dunner will provide guidance to patent counsel on the essentials of patent exclusivity that are in critical need of independent checking, and discuss crucial health checks on U.S. patent exclusivity for small molecules in Phase II efficacy trials and proceeding through large-scale randomized Phase III clinical trials, submission of the NDA, and subsequent approval and marketing.  The webinar will review the following issues:

    • What can be done if sub-optimal protection or even serious defects are discovered during the "health check"?
    • Are Orange Book listed patent claims definite or enabled under the current standards?
    • Is there a need for supplemental examination to clear the path to enforceability?

    The registration fee for the webcast is $297.  Those interested in registering for the webinar, can do so here.

  • The Knowledge GroupThe Knowledge Group will offer a webcast entitled "Managing and Defending Against Patent Infringement Lawsuits: Best Strategies and Practical Tips Explored" on February 20, 2018 from 3:00 to 4:00 pm (ET).  Blaney Harper of Jones Day and Peter D. Siddoway of Sage Patent Group, PLLC will discuss the most important aspects of managing as well as defending against patent infringement lawsuits, and present the best strategies as well as the best practices to avoid potential risks and pitfalls.  Key topics to be addressed by the webcast include:

    • Litigation Strategies against NPEs
    • Venue after TC Heartland
    • Considerations regarding whether to file an IPR
    • Damages Assessments and latest case law
    • Latest IPR Trends
    • Recent Court Decisions and Developments

    The registration fee for the webcast is $49.  Those interested in registering for the webinar can do so here.